Patent · US Active

Dosage form

US9504728B2 · kind B2 · utility

0Cited by

1References

7Claims

0Family size

Assignee

NEUROVIVE PHARMACEUTICAL AB · SE

Inventors

Matthew Alan Gregory · Bourn, GB
Steven Moss · Balsham, GB

Key dates

Filing date	Oct 24, 2012
Grant date	Nov 29, 2016
Priority date	—
Expiry date	Mar 1, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K47/44
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is provided inter alia a pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral administration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.